Cargando…

Dose‐Lowering in Contrast‐Enhanced MRI of the Central Nervous System: A Retrospective, Parallel‐Group Comparison Using Gadobenate Dimeglumine

BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoin...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeLano, Mark C., Spampinato, Maria Vittoria, Chang, Eric Y., Barr, Richard G., Lichtenstein, Richard J., Colosimo, Cesare, Vymazal, Josef, Wen, Zhibo, Lin, Doris D. M., Kirchin, Miles A., Pirovano, Gianpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290706/ https://www.ncbi.nlm.nih.gov/pubmed/34018290 http://dx.doi.org/10.1002/jmri.27731

Ejemplares similares

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison
por: Vaneckova, M, et al.
Publicado: (2015)

Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
por: Kirchin, M A, et al.
Publicado: (2015)

Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions
por: Schneider, Guenther, et al.
Publicado: (2015)

Severe Adverse Drug Reaction to Gadobenate Dimeglumine
por: Singer, Benjamin D., et al.
Publicado: (2009)

Comparison of Gadopentetate dimeglumine and Gadobenate dimeglumine in depiction of non-ischemic fibrosis in hypertrophic cardiomyopathy
por: Rudolph, Andre, et al.
Publicado: (2009)

The Unusual Suspect: Gadobenate-Dimeglumine Induced Kounis Syndrome
por: Choudhry, Faiza, et al.
Publicado: (2019)

Detection of Malignant Primary Hepatic Neoplasms with Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging: Results of Off-site Blinded Review in a Phase-II Multicenter Trial
por: Peña, Constantino S., et al.
Publicado: (2001)

Single dose gadobenate dimeglumine for imaging chronic of myocardial infarction in comparison to double dose gadopentetate dimeglumine
por: Bauner, Kerstin U, et al.
Publicado: (2009)

Nebulized liposomal gadobenate dimeglumine contrast formulation for magnetic resonance imaging of larynx and trachea
por: Wei, Xiaohui, et al.
Publicado: (2011)

A Comparison between Gadofosveset Trisodium and Gadobenate Dimeglumine for Steady State MRA of the Thoracic Vasculature
por: Camren, G. Paul, et al.
Publicado: (2014)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine
por: Violas, Xavier, et al.
Publicado: (2022)

Gadobenate Dimeglumine as an Intrabiliary Contrast Agent: Comparison with Mangafodipir Trisodium with Respect to Non-dilated Biliary Tree Depiction
por: Lim, Joon Seok, et al.
Publicado: (2005)

Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium
por: Nacif, Marcelo Souto, et al.
Publicado: (2018)

Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis
por: Li, Xiu-Mei, et al.
Publicado: (2017)

Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
por: Li, Yueming, et al.
Publicado: (2021)

Single-Dose Gadobutrol in Comparison With Single-Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 T
por: Wildgruber, Moritz, et al.
Publicado: (2014)

Use of oral gadobenate dimeglumine to visualise the oesophagus during magnetic resonance angiography in patients with atrial fibrillation prior to catheter ablation
por: Faletti, Riccardo, et al.
Publicado: (2014)

(18) F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine
por: Kirchner, Julian, et al.
Publicado: (2017)

Hypointense Hepatic Lesions Depicted on Gadobenate Dimeglumine-Enhanced Three-Hour Delayed Hepatobiliary-Phase MR Imaging: Differentiation between Benignancy and Malignancy
por: Hwang, Hye Sun, et al.
Publicado: (2009)

Imaging Findings of Hepatic Ewing’s Sarcoma on Computed Tomography and Gadobenate Dimeglumine-enhanced Magnetic Resonance Imaging: A Case Report and Literature Review
por: Lu, Tao, et al.
Publicado: (2022)

Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience
por: Park, Yulri, et al.
Publicado: (2010)

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study
por: Zech, Christoph J, et al.
Publicado: (2019)

Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study
por: Zeng, Fengxia, et al.
Publicado: (2022)

Safety and diagnostic efficacy of gadoteridol for magnetic resonance imaging of the brain and spine in children 2 years of age and younger
por: Shah, Chetan C., et al.
Publicado: (2021)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

The TRUTH confirmed: validation of an intraindividual comparison of gadobutrol and gadoteridol for imaging of glioblastoma using quantitative enhancement analysis
por: Kuhn, Matthew J., et al.
Publicado: (2021)

Neurotoxic Manifestations of an Overdose Intrathecal Injection of Gadopentetate Dimeglumine
por: Park, Kwan-Woong, et al.
Publicado: (2010)

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016)

A preoperative model based on gadobenate-enhanced MRI for predicting microvascular invasion in hepatocellular carcinomas (≤ 5 cm)
por: Zhang, Sisi, et al.
Publicado: (2022)

Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T
por: Besa, Cecilia, et al.
Publicado: (2015)

A case report of gadopentetate dimeglumine‐induced cardiac arrest: Resuscitation using extracorporeal membrane oxygenation
por: Fang, Honglong, et al.
Publicado: (2023)

Correlations from gadopentetate dimeglumine-enhanced magnetic resonance imaging after methotrexate chemotherapy for hemorrhagic placenta increta
por: Wehbe, Salim A, et al.
Publicado: (2003)

Volatile Decay Products in Breath During Peritonitis Shock are Attenuated by Enteral Blockade of Pancreatic Digestive Proteases
por: DeLano, Frank A., et al.
Publicado: (2017)

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model
por: Wang, Shu-ting, et al.
Publicado: (2019)

A Contrast Examination of Proinflammatory Effects on Kidney Function for γ-Fe(2)O(3) NP and Gadolinium Dimeglumine
por: Xie, Qian, et al.
Publicado: (2021)

Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy
por: Liu, Wanmin, et al.
Publicado: (2022)

Gadolinium retention and clearance after administration of macrocyclic magnetic resonance contrast agents to rats
por: Bussi, Simona, et al.
Publicado: (2019)

Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson’s Disease?
por: von Linstow, Christian U., et al.
Publicado: (2020)

Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury
por: Oguz, Ebru Gok, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ohg4tbcmr8c00073crc2i8r4lu